Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®)
Alzheimer's disease represents one of the most significant challenges in the field of neurology, affecting millions of individuals worldwide. In pursuing efficacious treatments, lecanemab has emerged as a promising therapeutic option. This pioneering monoclonal antibody targets and reduces amy...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2024-12-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/56711 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846101573239832576 |
|---|---|
| author | Adrianna Muciek Martyna Mocarska Anna Orłowska Katarzyna Strakowska Laura Opalska Anna Maryńczak Jan Mencel Nicole Nitschke |
| author_facet | Adrianna Muciek Martyna Mocarska Anna Orłowska Katarzyna Strakowska Laura Opalska Anna Maryńczak Jan Mencel Nicole Nitschke |
| author_sort | Adrianna Muciek |
| collection | DOAJ |
| description |
Alzheimer's disease represents one of the most significant challenges in the field of neurology, affecting millions of individuals worldwide. In pursuing efficacious treatments, lecanemab has emerged as a promising therapeutic option. This pioneering monoclonal antibody targets and reduces amyloid-beta plaques in the brain, a defining feature of Alzheimer's disease. By addressing one of the fundamental causes of the disease, lecanemab represents a novel approach to slowing its progression.
On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting marketing authorisation for Leqembi® (whose active substance is lecanemab). This recommendation is specifically directed towards patients with early-onset Alzheimer's disease who are non-carriers or heterozygotes for the apolipoprotein E ε4 (ApoE ε4) allele, thereby underscoring the drug's efficacy tailored to specific genetic profiles (Committee for Medicinal Products for Human Use, 2024).
The CHMP's approval is a testament to the extensive research and clinical trials that have demonstrated the efficacy and safety of Leqembi® (Lecanemab). This narrative review aims to provide a comprehensive examination of these aspects and offer a detailed understanding of the potential impact of this treatment on the management of early Alzheimer's disease.
|
| format | Article |
| id | doaj-art-a33a9c614e724a8ea6860f098b36de20 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-a33a9c614e724a8ea6860f098b36de202024-12-29T08:22:19ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182024-12-012510.12775/QS.2024.25.56711Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®)Adrianna Muciek0https://orcid.org/0009-0002-5678-3780Martyna Mocarska1https://orcid.org/0009-0007-4249-9857Anna Orłowska2https://orcid.org/0009-0000-6028-3004Katarzyna Strakowska3https://orcid.org/0009-0006-6202-2055Laura Opalska4https://orcid.org/0009-0007-3122-3484Anna Maryńczak5https://orcid.org/0000-0001-6187-0921Jan Mencel6https://orcid.org/0009-0006-0877-2242Nicole Nitschke7https://orcid.org/0009-0003-9817-7903The University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PLGabriel Narutowicz Municipal Specialist Hospital, Prądnicka 35 Street, 31-202 Kraków: Cracow, Malopolska, PLThe University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PLThe Ludwik Rydygier Memorial Specialized Hospital, Osiedle Złotej Jesieni 1, 31-820 Krakow: Cracow, Malopolska, PLThe University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PLClinical Provincial Hospital No. 2 them. Saint Jadwiga the Queen in Rzeszów, Lwowska 60 Street, 35-301 Rzeszów, Subcarpathia, PLIndependent Public Health Care Facility of the Ministry of Internal Affairs and Administration in Krakow, Kronikarza Galla 25 Street, 30-053 Krakow: Cracow, Malopolska, PLThe University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow: Cracow, Malopolska, PL Alzheimer's disease represents one of the most significant challenges in the field of neurology, affecting millions of individuals worldwide. In pursuing efficacious treatments, lecanemab has emerged as a promising therapeutic option. This pioneering monoclonal antibody targets and reduces amyloid-beta plaques in the brain, a defining feature of Alzheimer's disease. By addressing one of the fundamental causes of the disease, lecanemab represents a novel approach to slowing its progression. On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting marketing authorisation for Leqembi® (whose active substance is lecanemab). This recommendation is specifically directed towards patients with early-onset Alzheimer's disease who are non-carriers or heterozygotes for the apolipoprotein E ε4 (ApoE ε4) allele, thereby underscoring the drug's efficacy tailored to specific genetic profiles (Committee for Medicinal Products for Human Use, 2024). The CHMP's approval is a testament to the extensive research and clinical trials that have demonstrated the efficacy and safety of Leqembi® (Lecanemab). This narrative review aims to provide a comprehensive examination of these aspects and offer a detailed understanding of the potential impact of this treatment on the management of early Alzheimer's disease. https://apcz.umk.pl/QS/article/view/56711LeqembiLecanemabAlzheimer's diseaseBAN2401 |
| spellingShingle | Adrianna Muciek Martyna Mocarska Anna Orłowska Katarzyna Strakowska Laura Opalska Anna Maryńczak Jan Mencel Nicole Nitschke Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®) Quality in Sport Leqembi Lecanemab Alzheimer's disease BAN2401 |
| title | Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®) |
| title_full | Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®) |
| title_fullStr | Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®) |
| title_full_unstemmed | Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®) |
| title_short | Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®) |
| title_sort | advancements in early alzheimer s treatment narrative review about lecanemab leqembi r |
| topic | Leqembi Lecanemab Alzheimer's disease BAN2401 |
| url | https://apcz.umk.pl/QS/article/view/56711 |
| work_keys_str_mv | AT adriannamuciek advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT martynamocarska advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT annaorłowska advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT katarzynastrakowska advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT lauraopalska advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT annamarynczak advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT janmencel advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi AT nicolenitschke advancementsinearlyalzheimerstreatmentnarrativereviewaboutlecanemableqembi |